Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Der CEO kauft ein - und das gleich zweimal: Startschuss für die nächste Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DSSN | ISIN: US98985Y1082 | Ticker-Symbol: ZA8
Tradegate
28.03.25
08:00 Uhr
11,600 Euro
+0,800
+7,41 %
1-Jahres-Chart
ZYMEWORKS INC Chart 1 Jahr
5-Tage-Chart
ZYMEWORKS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,60010,80011:46
10,60010,80011:46
GlobeNewswire (Europe)
247 Leser
Artikel bewerten:
(1)

Zymeworks Inc.: Zymeworks Announces Participation in Upcoming Investor Conferences

Finanznachrichten News

VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

  • Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 4 at 8:45 am Eastern Time (ET) in Boston, MA.
  • Morgan Stanley 22nd Annual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 5 at 7:00 am ET in New York, NY.
  • H.C. Wainwright 26th Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 10 at 11:00 am ET in New York, NY.
  • 2024 Cantor Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 18 at 3:05 pm ET in New York, NY.

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric technology. Zymeworks has entered into separate agreements with BeiGene, Ltd.and follow @ZymeworksIncon X.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications


© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.